Gb-0998 (intravenous immunoglobulin) (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00515450 (ClinicalTrials.gov) | July 2007 | 10/8/2007 | Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis | A Randomized, Controlled Clinical Study of GB-0998 for Treatment of Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | Biological: GB-0998 (Intravenous immunoglobulin);Procedure: Plasmapheresis | Benesis Corporation | NULL | Completed | 16 Years | N/A | Both | 46 | Phase 3 | Japan |